Clinical Trials Browser

Withdrawn × enfortumab vedotin × Clear all

NCT07217496 2026-03-17

N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer

Phase 1 Withdrawn

Carcinoma, Transitional Cell